Diagnostic Value of Portal Vein Velocity for Portal Hypertension in Patients with Hepatitis B Virus-related Cirrhosis
- 1 November 2021
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Current Medical Imaging
- Vol. 17 (11), 1363-1368
- https://doi.org/10.2174/1573405617666210225090948
Abstract
Background: Portal vein velocity (PVV) has shown reasonable correlation with the presence of portal hypertension in patients with cirrhosis. This study aims to evaluate the value of PVV for diagnosing clinically significant portal hypertension (CSPH) and predicting the risk of variceal hemorrhage (VH) in patients with hepatitis B virus (HBV)-related cirrhosis. Material and Methods: A cohort of 166 consecutive adult patients with HBV-related cirrhosis was recruited in this retrospective study from two high-volume liver centers in China between April 2015 and April 2017. The performance of PVV and other non-invasive parameters for diagnosing CSPH and predicting risk of VH were studied. Results: PVV demonstrated the best performance for diagnosing CSPH (defined as an HVPG ≥10 mmHg) in patients with HBV-related cirrhosis among the included noninvasive predictors with the area under the receiver operating characteristic curve (AUC), specificity, and sensitivity of 0.745, 50%, and 93.5%, respectively. Other noninvasive markers, including APRI, AAR, LS, FIB-4, and diameter of portal vein, did not show sufficient performance with the AUCs of 0.565, 0.560, 0.544, 0.529, and 0.474, respectively. With regard to predicting the risk of VH (defined as an HVPG ≥12 mmHg), PPV also exhibited a moderate performance with an AUC of 0.762, which was superior to that of the aforementioned markers. By using two cutoff values of PVV to rule-out (11.65 cm/s) and rule-in (20.20 cm/s) CSPH, 30 (33.7%) patients showed definite results categories, with 23 (76.7%) patients were well classified and 7 (23.3%) were misclassified. Fifty-nine (66.3%) patients were with indeterminate results. By using PVV values of 13.10 cm/s and 21.40 cm/s to rule-out and rule-in HVPG ≥ 12mmHg, 34 (38.2%) patients has definite results, among whom 26 (76.5%) were well classified and 8 (23.5%) were misclassified. And 55 (61.8%) patients required further evaluation. Conclusion: PPV is not good enough to serve as a non-invasive parameter for identifying CSPH and predicting risk of VH in patients with HBV-related cirrhosis.Keywords
This publication has 15 references indexed in Scilit:
- The global burden of liver disease: The major impact of ChinaHepatology, 2014
- Liver cirrhosisThe Lancet, 2014
- Invasive and non-invasive techniques for detecting portal hypertension and predicting variceal bleeding in cirrhosis: A reviewAnnals of Medicine, 2013
- Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosisHepatology, 2009
- Thrombotic risk factors in patients with liver cirrhosis: Correlation with MELD scoring system and portal vein thrombosis developmentJournal of Hepatology, 2009
- Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver diseaseHepatology, 2009
- Liver stiffness measurement as a predictive tool of clinically significant portal hypertension in patients with compensated hepatitis C virus or alcohol‐related cirrhosisAlimentary Pharmacology & Therapeutics, 2008
- Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosisHepatology, 2007
- Portal and splenic hemodynamics in cirrhotic patients: relationship between esophageal variceal bleeding and the severity of hepatic failureThe Esophagus, 2004
- Captopril reduces portal pressure effectively in portal hypertensive patients with low portal venous velocityThe Esophagus, 2003